Kangmei Pharmaceutical Co., Ltd Class A

Kangmei Pharmaceutical Co., Ltd Class A

SSSE:600518
1.28
CNY
-0.01
(-0.78%)
0.01EPS
214.52P/E
18.53BMarket Cap
Kangmei Pharmaceutical Co., Ltd Class A
SSE:600518
(Shanghai Stock Exchange)

Recent

price

1.28

P/E

ratio

214.52

div

yld

0.00%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.98
1.41
2.54
3.04
3.63
4.08
4.32
3.17
1.38
2.43
0.39
0.3
0.3
0.48
0.36
0.36
0.33
Revenue per Share
0.21
0.23
0.33
0.43
0.52
0.62
0.67
0.39
0.03
-0.99
-2.25
0.57
-0.19
0.01
- -
- -
0.01
Basic EPS, GAAP
-0.03
-0.4
-0.09
0.22
0.1
-0.2
0.01
-1.26
-0.35
0.51
0.05
- -
-0.06
-0.04
-0.03
-0.01
- -
Free Cash Flow per Basic Share
0.04
0.06
0.09
0.17
0.24
0.25
0.39
0.4
0.24
0.54
0.07
- -
- -
- -
- -
- -
- -
Dividend per Share
1.24
2.1
2.41
2.74
3.13
3.59
5.29
5.12
4.55
3.53
-2.71
0.72
0.5
0.51
0.52
0.53
0.53
Book Value per Share
0.86
1.62
1.94
2.29
2.83
3.28
4.82
4.6
4.06
3.1
-2.99
0.67
0.46
0.47
0.48
0.49
0.5
Tangible Book Value per Share
3,391
4,313
4,401
4,397
4,396
4,425
5,008
5,541
12,359
4,710
13,815
13,891
14,148
10,252
14,289
14,754
14,513
Basic Weighted Avg Shares
3,309
6,081
11,165
13,359
15,949
18,067
21,642
17,579
17,065
11,446
5,412
4,153
4,180
4,874
5,189
5,252
4,820
Sales/Revenue/Turnover
25.95
21.46
17.78
18.72
19.24
20.55
21.59
22.87
16.2
-9.16
-35.31
392.55
-24.25
0.93
0.49
2.13
2.71
Operating Margin (%)
90
114
168
231
279
299
378
440
500
695
645
603
366
346
340
311
- -
Depreciation Expense
716
1,005
1,441
1,880
2,286
2,757
3,340
2,150
374
-4,661
-31,085
7,918
-2,688
103
9
10
91
Net Income, GAAP
14.13
14.84
14.84
15.07
15.56
14.99
16.32
25.51
44.97
- -
- -
2.89
- -
6.16
65.13
71.17
18.28
Effective Tax Rate (%)
21.62
16.53
12.91
14.07
14.33
15.26
15.43
12.23
2.19
-40.72
-574.37
190.68
-64.31
2.1
0.17
0.2
1.88
Profit Margin (%)
2,976
7,405
7,764
7,509
12,406
15,569
24,437
26,591
25,939
19,183
-4,781
3,338
1,942
710
1,007
1,386
1,729
Working Capital
1,615
3,654
3,311
2,698
2,501
4,886
4,889
8,307
17,463
15,010
19,556
153
199
188
95
70
73
LT Debt
4,926
9,248
10,583
12,030
16,719
18,838
29,383
28,515
25,711
20,651
-10,410
9,968
6,984
7,080
7,209
7,325
7,421
Total Equity
9.88
8.88
9.48
10.77
10.94
10.58
9.26
4.57
0.71
- -
- -
68.68
- -
1.37
-0.15
0.17
1.07
Return on Invested Capital (%)
12.18
11.21
11.49
13.05
13.26
12.73
11.49
6.57
2.64
- -
- -
57.43
- -
2.11
0.17
0.18
1.37
Return on Capital (%)
15.56
14.18
14.54
16.63
17.74
18.66
15.93
8.33
1.56
-23.21
- -
- -
-31.86
1.47
0.12
0.14
1.24
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
105
102
80
LT Borrowings
- -
- -
- -
LT Finance Leases
69
67
73
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
13,829
13,829
13,829
Market Capitalization
24,477
16,595
18,531

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
6,803
6,660
6,619
Cash, Cash Equivalents & STI
1,229
1,345
1,363
Accounts Receivable, Net
2,368
2,189
2,123
Inventories
2,379
2,304
2,391
Total Current Liabilities
5,378
5,097
4,890
Payables & Accruals
- -
- -
- -
ST Debt
105
102
80
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-34.78%
-44.18%
1.62%
Free Cash Flow
-2,219.1%
-435.47%
-78.4%
Net Income, GAAP
-130.9%
-86.88%
20.46%
Sales/Revenue/Turnover
-8.59%
0.34%
1.22%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,201
1,273
1,399
1,316
5,189
2025
1,299
1,278
- -
1,293
5,252
2026
1,080
1,211
1,237
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Kangmei Pharmaceutical Co., Ltd. (600518.SS) engages primarily in the research, development, production, and sale of traditional Chinese medicines, proprietary Chinese medicines, chemical preparations, health foods, and related products in China. The company operates an integrated model across the traditional Chinese medicine industry chain, with core offerings that include Chinese medicine tablets such as Ganmaoling Granule for colds and flu and Qingkailing Capsules for immune support; herbal ingredients like American ginseng, angelica, honeysuckle, notoginseng, radix codonopsis, and salvia; chemical drugs including clarithromycin, doxazosin mesylate, paracetamol and pseudoephedrine hydrochloride, and propiverine hydrochloride; as well as health foods, medical equipment, and pharmaceutical logistics services through medical institutions, smart pharmacies, OTC retail, chain drug stores, direct sales, and e-commerce channels. It maintains over 30 branches nationwide, focusing on the domestic market while pursuing international expansion into Southeast Asia, and also engages in property management and hospital operations. Founded in 1997 by Ma Xingtian in Puning, Jieyang, Guangdong province, the company is headquartered in Shenzhen, Guangdong, with additional facilities in Puning, and listed on the Shanghai Stock Exchange in March 2001. Kangmei Pharmaceutical became actually controlled by Guangdong Shennong Enterprise Management Partnership (Limited Partnership) following the introduction of state-owned capital and industry investors in 2021 as part of its restructuring efforts after a major 2019 financial scandal involving overstated revenues, profits, and cash holdings. In recent developments, the company received CNY 6.5 billion in funding from Guangdong Shennong Enterprise Management Partnership; signed a settlement agreement in July 2025 with Guangzhou Pharmaceutical Group Co., Ltd. to resolve historical debts of RMB 43.5 million via its subsidiary Chengdu Kangmei Pharmaceutical Co., Ltd.; and continues to implement its "12355" Global Strategy, emphasizing traditional Chinese medicine tablets, smart pharmacies, and big health industry expansion. As of 2025, Kangmei reports ongoing operational activities, including Q3 performance briefings and semi-annual results announcements, amid efforts to stabilize post-restructuring with total assets previously valued at around CNY 47.2 billion.